Simplex Trading, LLC Dia Medica Therapeutics Inc. Transaction History

Simplex Trading, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 02, 2024	SELL	$2.05 - $2.99 $1,104 - $1,611	-539 Reduced 52.84%	481 $1,000
Q3 2023 Nov 01, 2023	BUY	$2.56 - $4.4 $2,094 - $3,599	818 Added 404.95%	1,020 $2,000
Q2 2023 Aug 04, 2023	SELL	$1.53 - $4.4 $5,085 - $14,625	-3,324 Reduced 94.27%	202 $0
Q1 2023 Apr 27, 2023	SELL	$1.32 - $1.89 $1,368 - $1,959	-1,037 Reduced 22.73%	3,526 $5,000
Q4 2022 Feb 02, 2023	BUY	$1.13 - $1.62 $2,890 - $4,143	2,558 Added 127.58%	4,563 $7,000
Q3 2022 Nov 04, 2022	BUY	$1.2 - $2.07 $2,406 - $4,150	2,005 New	2,005 $2,000
Q1 2022 May 02, 2022	SELL	$2.29 - $3.88 $14,541 - $24,638	-6,350 Closed	0 $0
Q4 2021 Feb 23, 2022	SELL	$3.43 - $4.65 $34,269 - $46,458	-9,991 Reduced 61.14%	6,350 $23,000
Q3 2021 Oct 28, 2021	SELL	$3.1 - $4.32 $310 - $432	-100 Reduced 0.61%	16,341 $70,000
Q2 2021 Aug 12, 2021	BUY	$4.45 - $9.91 $72,032 - $160,413	16,187 Added 6372.83%	16,441 $73,000
Q1 2021 Apr 26, 2021	BUY	$7.76 - $10.43 $1,971 - $2,649	254 New	254 $2,000

3.87M

1.3K

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $116M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.